Search

The article discusses a phase II clinical trial comparing the effects of folate receptor alpha dendritic cells (FRaDCs) to a placebo in treating patients with advanced stage ovarian cancer. FRaDCs are a type of dendritic cell vaccine made from a person's white blood cells and target a protein found in high levels on ovarian tumor cells. The trial aims to evaluate the efficacy of FRaDCs in preventing or delaying recurrence in patients with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The study is set to be completed by December 31, 2027, and focuses on outcomes such as recurrence-free survival and overall survival in patients receiving FRaDCs compared to a placebo. [Extracted from the article]

A study conducted at the Mayo Clinic in Jacksonville, Florida, focused on the outcomes of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who underwent anti-CD19 chimeric antigen receptor T-cell therapy (CART). The study examined the impact of bridging treatment with radiotherapy on relapse-free survival, event-free survival, and overall survival. Results showed that patients who received bridging radiotherapy had higher response rates, improved local control, and better survival outcomes compared to those who did not receive radiotherapy. The research concluded that radiotherapy before CART for patients with limited disease sites improves outcomes without significant toxicities. [Extracted from the article]

A study conducted at Ghent University in Belgium examined the impact of early initiation of antiretroviral therapy (ART) during acute HIV infection (AHI) on immunovirological outcomes. The study collected longitudinal clinical data and human bodily material (HBM) from participants diagnosed and treated during AHI. The findings showed that early initiation of ART during AHI had a beneficial effect on long-term immunovirological outcomes, regardless of the stage of infection at treatment initiation. The study also demonstrated that collecting HBM during and after AHI was safe and feasible. The researchers emphasized the importance of comprehensive cohorts that integrate clinical data with high-quality HBM samples to study the impact of early ART on reservoir dynamics and immune responses across various anatomical sites after AHI. [Extracted from the article]

Anixa Biosciences, a biotechnology company focused on cancer treatment and prevention, has submitted a protocol amendment for its ongoing clinical trial using CAR-T therapy to treat ovarian cancer. The amendment allows for a second dose of the therapy to be given to patients who may benefit from it. Previously, a single patient was approved for a second dose based on positive results, but this amendment will allow all potential patients to receive a second dose without individual applications. The company is hopeful that higher cell doses and a second dose will improve the efficacy and outcomes of the treatment. [Extracted from the article]

The Memorial Sloan Kettering Cancer Center is conducting a Phase I clinical trial, NCT06623396, to investigate the safety and effectiveness of intraperitoneal mesothelin-targeted CAR T-cell therapy in patients with mesothelin-positive esophagogastric adenocarcinoma with peritoneal carcinomatosis. The trial aims to enroll 18 participants who will have their white blood cells collected and modified in the laboratory to become MSLN-targeted CAR T cells. The therapy will be administered over a 3-4 week period. The document provides detailed criteria for inclusion and exclusion in the trial, including timeframes for obtaining tissue samples and medical conditions that would prevent enrollment. The study is open to individuals of all genders aged 18 years and older. Administrative information, such as the study ID number and data sharing plan, is also included. [Extracted from the article]

A clinical trial, NCT06610344, is currently underway to investigate the feasibility and safety of b-hydroxybutyrate (BHB) supplementation in lymphoma patients undergoing anti-CD19 CAR T-cell therapy. The study aims to determine if BHB supplementation is well-tolerated and if it leads to changes in the gut microbiome and peripheral blood mononuclear cells. The trial is using a commercially available BHB supplement called HVMN Ketone-IQ and is expected to be completed by October 2025. Additionally, another clinical trial is being conducted in the United States, led by Dr. Elise Chong, to study the effects of R-1,3-Butanediol, a dietary supplement, on patients with large B-cell lymphoma undergoing anti-CD19 CAR-T therapy. This trial will enroll 5 participants and is expected to be completed by October 15, 2026. The eligibility criteria for participants are outlined in the document. [Extracted from the article]

A study conducted at Oslo University Hospital in Norway examined the management of hyperleukocytosis in pediatric acute myeloid leukemia (AML). The researchers recommended immediate initiation of full-dose chemotherapy using etoposide monotherapy without leukapheresis or prephase chemotherapy. The study found that this approach was feasible, safe, and effective, with a reduction in white blood cell count comparable to leukapheresis. The five-year event-free and overall survival rates for patients with hyperleukocytosis were slightly lower than those without hyperleukocytosis. The researchers concluded that early initiation of induction chemotherapy is crucial for managing hyperleukocytosis in pediatric AML. [Extracted from the article]

Researchers from Universite Paris Cite have published a study on the use of neurofilament light chain (NfL) levels as a predictive biomarker for neurotoxicity after CAR T-cell therapy. The study found that elevated NfL levels at the time of CAR T-cell infusion were associated with the severity of immune effector cell-associated neurotoxicity syndrome (ICANS). The researchers concluded that incorporating NfL levels into the decision-making process could help guide the management of ICANS and determine the appropriate CAR product for each patient. This research provides valuable insights for the development of personalized treatments for patients undergoing CAR T-cell therapy. [Extracted from the article]

Global Life Sciences Solutions USA LLC has been issued a patent for an apparatus for fluid line management in a bioprocessing system. The invention relates to the production of cellular immunotherapies, specifically chimeric antigen receptor (CAR) T cell therapy. The system aims to reduce contamination risk by increasing automation and decreasing human handling, while also providing flexibility and consistency in volume production. The patent describes the components and features of the system, including a tray, pump assembly, pinch valve array, and tubing module. [Extracted from the article]

A clinical trial has been launched to investigate the potential cure of HIV infection in patients who have undergone a stem cell transplant. The trial involves closely monitoring patients whose blood shows no detectable levels of the HIV virus after leukapheresis, a process of collecting blood. These patients will discontinue their antiretroviral therapy (ART) and be regularly tested and monitored for up to 52 weeks. If they remain HIV-free during this period, they may be considered cured of their HIV infection. The trial is currently in the recruitment phase and aims to enroll 10 participants. [Extracted from the article]

This document provides information about a clinical trial in China, NCT06567366, which is investigating the use of a drug called Glofitamab in combination with CAR T-cell therapy for the treatment of large B-cell lymphoma. The trial aims to evaluate the efficacy and safety of this treatment option and will assess various outcome measures such as response rates, duration of response, and survival rates. The trial is currently in the interventional phase and is designed as a single-group trial with the primary purpose of treatment. Eligible participants must have relapsed or refractory lymphoma and meet certain prognostic factors. The trial is not yet recruiting participants, and it is projected to be completed in September 2027. [Extracted from the article]

The article focuses on a clinical trial assessing the safety, side effects, and optimal dosage of the drug NEXI-001 combined with decitabine and lymphodepleting chemotherapy for treating relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) following allogeneic hematopoietic cell transplantation. It explains that the study aims to determine the recommended dose and evaluate the treatment's anti-leukemic activity, including response rates and survival outcomes.

This document provides information about a clinical trial, NCT06561425, that is currently recruiting participants to evaluate the feasibility, safety, and efficacy of an experimental treatment called GLPG5101 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). The trial aims to determine the optimal dose of GLPG5101 with the fewest side effects in the first phase, and in the second phase, all participants will receive the best dose identified. The trial will assess various outcome measures, including adverse events, objective response, duration of response, and survival rates. The trial is open to individuals with aggressive DLBCL, FL, MZL, MCL, BL, PCNSL, relapsed or refractory disease, and adequate bone marrow, renal, hepatic, and pulmonary function. The trial is being conducted in the United States, Belgium, and the Netherlands, and contact information for further inquiries is provided. [Extracted from the article]

The article focuses on a Phase 2, open-label, randomized clinical trial evaluating the combination of pirtobrutinib and brexucabtagene autoleucel in patients with relapsed or refractory mantle cell lymphoma. Topics include the study design and goals, which involve assessing progression-free survival and comparing the efficacy and safety of concurrent pirtobrutinib versus no concurrent pirtobrutinib, as well as the secondary outcomes related to severe adverse events and overall response rates.

A recent study conducted at Zhongnan Hospital of Wuhan University explored the use of leukapheresis, a procedure that reduces white blood cell count, in patients with hyperleukocytic acute myeloid leukemia. The study found that leukapheresis treatment resulted in a significant decrease in white blood cells and a decrease in infection rates compared to non-apheresis treatment. However, the study also noted that leukapheresis treatment can be damaging to cells and that the optimal centrifugation parameters need to be determined to minimize cell damage. The research concluded that the cells obtained under the optimal centrifugation parameters can be successfully cryopreserved and used to establish leukemia animal models, which can improve the efficiency and reduce the side effects of leukapheresis. [Extracted from the article]

A recent study conducted at the University of Houston explores the potential of microfluidic cell separation methods to enable centrifugation-free, low extracorporeal volume (ECV) leukapheresis in pediatric patients. Leukapheresis is a procedure used to remove white blood cells from a patient's blood. The study highlights the challenges and advancements in passive separation methods and discusses their potential for future use as a high-throughput microfluidic leukapheresis platform. The research was supported by the NIH National Heart Lung & Blood Institute (NHLBI) and has been peer-reviewed. [Extracted from the article]

A recent report from University Hospital Vall d'Hebron in Barcelona, Spain, discusses the use of bendamustine-containing regimens as bridging therapy (BT) for patients with relapsed/refractory large B-cell lymphoma (LBCL) who are receiving chimeric antigen receptor (CAR) T-cell therapy. The study aimed to assess the impact of bendamustine on CAR-T outcomes and found that BT with bendamustine-containing regimens was safe and did not negatively affect CAR-T efficacy or patient survival. The research suggests that bendamustine can be a potential option for BT in these patients. The study was supported by Instituto de Salud Carlos III, Asociacion Espanola contra el Cancer, and Generalitat de Catalunya. [Extracted from the article]

This document provides information about an ongoing clinical trial conducted by Tianjin Medical University Cancer Institute and Hospital in China. The trial, with the NCT number NCT06484790, aims to evaluate the safety and effectiveness of autologous TCR-T cell therapy in individuals with advanced solid tumors. Specifically, the trial focuses on the use of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumors. The study is currently in the recruiting phase and is expected to be completed by April 2026. The trial is open to both male and female participants aged 18 to 75 and focuses on pancreatic cancer, colorectal cancer, and lung adenocarcinoma cancer. Contact information for the primary and backup contacts for the trial is also provided. [Extracted from the article]

This document provides information about a clinical trial in China for the treatment of relapsed or refractory large B-cell lymphoma (LBCL). The trial is studying the use of a biological treatment called Relma-cel, which involves the administration of CAR+T cells. The study aims to evaluate the effectiveness, safety, and pharmacokinetics of Relma-cel in LBCL patients. The trial is currently in the interventional phase and is expected to be completed by April 2025. [Extracted from the article]

A report from Albany Medical College discusses new findings on sepsis, a condition that can lead to immune dysfunction, hematological changes, and increased risk of infection. The research used a surgical model of murine sepsis to analyze the long-term impacts on hematopoiesis, the process of blood cell formation. The study found that sepsis survivors did not exhibit emergency myelopoiesis and hematopoietic stem and progenitor cell mobilization in response to treatment with granulocyte colony-stimulating factor (G-CSF). These findings contribute to a better understanding of how sepsis can predispose individuals to subsequent infections. [Extracted from the article]

Immatics Us Inc. has been issued a patent for methods of manufacturing T cells for adoptive T cell therapy (ACT). The patent describes a method for preparing T cells by isolating CD8+ T cells from a blood sample, culturing them in the presence of cytokines, and then contacting them with a multimer containing a target peptide in complex with an MHC molecule. The contacted T cells are sorted and expanded for use in ACT. The patent claims also include the use of binding agents, protein kinase inhibitors, and a closed system for sorting and expanding the T cells. This patent provides a solution for the simple and cost-effective manufacturing of T cells for ACT. [Extracted from the article]

A patent has been issued to Fenwal Inc. for systems and methods that increase the volume of Immunoglobulin G (IgG) collected during plasmapheresis procedures. Plasmapheresis is a process where whole blood is withdrawn from a donor, the plasma is separated from the cellular blood components, and the cellular blood components are returned to the donor. The patent describes a method that maximizes the volume of whole blood processed during the first draw phase, resulting in increased IgG collection. This innovation could lead to higher volumes of IgG being produced at plasma collection centers, benefiting patients who require plasma-derived therapies. [Extracted from the article]

This document provides information about a clinical trial currently recruiting participants at Fudan University in China. The trial, NCT06445803, is studying the use of anti-CD19/CD22 CAR T cells (KQ-2002) in adults with recurrent or refractory acute lymphoblastic leukemia or non-Hodgkin's lymphoma. The trial involves screening, cell collection, lymphodepleting chemotherapy, and CAR T cell infusion. Patients will be followed for two years after the cell infusion to monitor for potential long-term side effects. The study is in Phase 1 and is non-randomized. The trial is expected to be completed in December 2026. [Extracted from the article]

A recent study conducted at the Mayo Clinic in Rochester, Minnesota, examined the factors that contribute to severe cytopenia and therapy-related myeloid neoplasms (t-MN) in patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy for hematological malignancies. The study found that advanced age, anemia, and thrombocytopenia at the time of evaluation for CAR-T eligibility were associated with the development of post-treatment severe cytopenia and t-MN. The researchers recommend further multi-center studies to validate these findings. This information is valuable for patients and healthcare providers in making informed decisions about CAR-T therapy and stem cell collection. [Extracted from the article]

A preprint abstract discusses the potential benefits of point-of-care (POC) manufacturing of Chimeric Antigen Receptor T (CAR T) cell therapy in Saudi Arabia. The current commercial CAR T manufacturing process is complex and time-consuming, involving shipping cells to a centralized facility. The study presents the outcomes of large-scale, in-house POC CAR T manufacturing, demonstrating successful generation of CAR T cells within a shortened production period. The results indicate that in-house POC manufacturing eliminates the need for third-party shipping logistics and enables regulatory-compliant production of CAR T cells. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

A research report from Sao Paulo State University (UNESP) in Botucatu, Brazil, discusses the comparison of techniques for corneal epithelium cell culture to collect conditioned medium for the differentiation of mesenchymal stem cells. The study evaluated five different culture techniques and found that using flasks with hydrophilic surface treatment resulted in the highest yield of conditioned culture medium. Other techniques, such as enzymatic digestion and corneal scraping, showed contamination with corneal fibroblasts. The effectiveness of cell differentiation was confirmed through cytometry analysis. The researchers concluded that the culture of corneal epithelial cell explants in flasks with hydrophilic surface treatment is the best technique for collecting a higher yield of conditioned culture medium for differentiating mesenchymal stem cells. [Extracted from the article]

AstraZeneca has conducted research on the cryopreservation and banking of patients' leukapheresis materials for CAR-T cell therapies. The study aimed to determine the optimal temperature range for transferring cryopreserved materials from controlled rate freezers to ultracold storage without affecting CAR-T cell production and functionality. The findings showed that there is no significant influence on CAR-T cell expansion, differentiation, or in-vitro function when transferring materials at temperatures ranging from -30 degrees C to -80 degrees C. This research suggests that cryopreserved materials can be safely transferred at higher temperatures for autologous CAR-T cell therapies. [Extracted from the article]

A recent study conducted by Mayo Clinic in Rochester, Minnesota, evaluated the user experience and DNA yield from self-collection devices used in laboratory medicine. The study found that while DNA quality and quantity were comparable between devices, users preferred direct saliva collection over swab-based devices. The research highlights the importance of clear instructions and user compliance in downstream testing of collected biospecimens. The findings can guide future experiments in human RNA, microbial, or viral sample collection and clinical testing. The study was published in The Journal of Applied Laboratory Medicine and more information can be found at the provided link. [Extracted from the article]

A patent application has been filed for a bispecific nanoparticle system designed to target cancer cells. The system utilizes a silicon dioxide core with gold nanospheres conjugated to tumor cell targeting domains and T-cell targeting domains. The nanoparticle system aims to increase T-cell-mediated death of tumor cells and has the potential to be used in CAR-T cell therapy. This technology could address challenges faced by immunotherapy in treating solid tumors and reduce the time and resources required for manufacturing personalized CAR-T cells. [Extracted from the article]

The patent application titled "Expedited Administration of Engineered Lymphocytes" outlines a method for manufacturing and administering engineered lymphocytes to treat cancer. The process involves obtaining lymphocytes from a patient, modifying them with a polynucleotide vector, culturing the modified lymphocytes, and reintroducing them into the patient within 28 days. This method aims to reduce the risk of thrombocytopenia and has shown promising response rates. Additionally, the application discusses methods for predicting treatment outcomes and the likelihood of thrombocytopenia in patients receiving immunotherapy. The patent application specifically focuses on preventing and reducing thrombocytopenia in patients with relapsed/refractory large B-cell lymphoma. [Extracted from the article]

A patent application has been submitted for a system and method that allows for real-time modifications of patient cells. This system enables the customization of cell-based therapies and treatments, including the production of CAR-T cells. The process involves removing target nucleated blood cells from the patient, modifying them in real time, and then returning them to the patient. This eliminates the need for manipulating cells outside of the body and allows for the delivery of modified cells directly to the patient. The system can be used to treat various conditions, such as cancer, sickle cell anemia, hemophilia, and beta-thalassemia, and can be controlled and monitored using a processor module. [Extracted from the article]

A patent application titled "Custom Data Fields For Automated Apheresis Procedures" has been published online by the US Patent and Trademark Office. The patent application, filed by Matthew J. Schoonover, describes a method and system for processing blood or blood products using an automated system with a programmable controller and an interactive display screen. The system allows operators to customize the display of information during blood processing procedures, including pre-procedure estimates, intra-procedure variables, and post-procedure summaries and results. The patent application was assigned to Fenwal Inc. and provides potential solutions for improving the efficiency and accuracy of automated apheresis procedures. [Extracted from the article]

A report from the Zhejiang University School of Medicine in Hangzhou, China, discusses the psychological and physical side effects experienced by donors of allogeneic hematopoietic cell transplantation (allo-HCT) during granulocyte colony-stimulating factor mobilization. The study analyzed 349 consecutive related peripheral blood stem cell (PBSC) donors and found that higher baseline blood cell counts were positively correlated with CD34 cell counts, while female donors and older age were negatively related. Physical side effects such as bone pain and fatigue were more frequent in female and older donors. The study also found that depression, anxiety, and insomnia scores increased during the mobilization period, and poor psychological status of the donor can aggravate physical side effects. [Extracted from the article]

A recent study conducted by researchers at the Institute Curie highlights the effectiveness of CAR T-cell therapy in treating relapsed primary central nervous system lymphoma (PCNSL). The study, which included the largest cohort of PCNSL patients treated with CAR T-cells worldwide, found that the therapy induced a high rate of prolonged remission and had a reassuring tolerance profile. The results of the study were significantly better than those typically observed in this setting. This research provides valuable insights into the potential of CAR T-cell therapy for the treatment of PCNSL. [Extracted from the article]

A clinical trial, NCT06350110, is being conducted in China by Essen Biotech to investigate the use of BH002 injection (CD19-BCMA CAR-T cells) in treating patients with resistant systemic lupus erythematosus (SLE). The trial aims to determine the highest dose of the injection that patients can tolerate. SLE is an autoimmune disorder characterized by the production of autoantibodies, and conventional treatment aims to achieve remission. CD19-BCMA CAR-T cells offer a potential solution by targeting and eliminating abnormal B cells responsible for antibody production. The trial will evaluate the safety and effectiveness of this new treatment approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy for patients with specific hematologic malignancies. The treatment regimen involves the administration of fludarabine phosphate and cyclophosphamide before the infusion of CD19/BCMA-CAR T cells. Eligible patients may receive additional doses if they respond well to the initial infusion. The trial is not yet recruiting and is estimated to be completed by December 2025. [Extracted from the article]

A study conducted by researchers at Washington University in St. Louis investigated the impact of bridging therapy (BT) on the outcome of patients with relapsed/refractory large B-cell lymphoma who received antilymphoma treatment between leukapheresis and axicabtagene ciloleucel (axi-cel) infusion. The study analyzed data from the multicenter US Lymphoma CAR-T Consortium and found that patients who received BT had similar outcomes to those who did not receive BT in terms of overall response rate, complete response rate, progression-free survival, and overall survival. The study also found that radiation-based BT did not provide clear advantages over nonradiation-based BT. These findings suggest that BT may be safe without significantly impacting long-term survival for patients who require disease stabilization during the manufacturing period. [Extracted from the article]

A recent preprint abstract discusses the potential of tumor cell-based liquid biopsy for cancer patients. The abstract highlights the challenges of isolating circulating tumor cells (CTCs) due to their rarity and the limitations of current technologies. The researchers describe a high-throughput microfluidic prototype that can process large blood volumes and isolate a sufficient number of CTCs for analysis. This technology allows for the characterization of CTCs' morphological and molecular heterogeneity, including gene copy number variation, which has potential diagnostic applications. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted at Toyohashi Municipal Hospital in Japan has found that measuring hematopoietic progenitor cells (AP-HPCs) in leukapheresis products using Sysmex XN-series analyzers can help determine if a sufficient number of CD34+ stem cells have been collected. This is particularly important when using plerixafor, a stem cell-mobilizing drug that requires administration the day before leukapheresis. The study found a strong correlation between AP-CD34+ and AP-HPC counts, with AP-HPCs being able to identify cases where enough stem cells have been collected. This research has been peer-reviewed and published in Internal Medicine. [Extracted from the article]

A clinical trial, NCT06297408, is being conducted in China to assess the safety and effectiveness of Relma-cel in treating moderate to severe active systemic lupus erythematosus (SLE). The trial aims to compare the efficacy of Relma-cel with conventional therapy. The study is currently in the interventional phase and is not yet recruiting participants. The estimated completion date for the trial is May 2026. The eligibility criteria for the study include age, diagnosis of SLE, active disease despite previous treatments, and specific requirements related to organ function, infection history, contraceptive use, and exclusion criteria such as previous CAR-T cell therapy or major organ transplantation. The study is being conducted by Shanghai Ming Ju Biotechnology Co., Ltd. and further information can be obtained from JW Medical. [Extracted from the article]

A patent has been issued for a bioprocessing system and methods for the production of cellular immunotherapies. The system aims to reduce contamination risk by increasing automation and decreasing human handling. It consists of three modules: one for enriching and isolating cells, one for activating and genetically modifying the cells, and one for harvesting the expanded cells. The system allows for parallel and asynchronous processing of multiple populations of cells and is designed to be flexible and adaptable to different customer processes. [Extracted from the article]

A recent study conducted in Milan, Italy, has found that CD19-targeted CAR T-cell therapy can induce durable remissions in relapsed/refractory large B-cell lymphomas (R/R LBCL), but 60% of patients do not respond or relapse. The researchers performed transcriptomic and functional evaluations of leukapheresis products in 95 R/R LBCL patients and identified a signature composed of 4 myeloid genes expressed by T cells isolated from leukapheresis products that can predict patients with a very short progression-free survival. The study also found that high circulating absolute monocyte counts at the time of leukapheresis negatively influenced response and progression-free survival. This research highlights the need to incorporate monocyte depletion strategies for better CAR T production and could be used to plan trials evaluating CAR T cells versus other novel treatments or allogeneic CAR T cells. [Extracted from the article]

The article offers information on Natural Killers cell therapies which offer a potentially cheaper and safer route to cancer treatment than their T cell–based predecessors. It mentions Chimeric antigen receptor (CAR) T cell therapies, as they are known, involve harnessing the patient's own immune cells, genetically modifying them with cancer specific receptors for maximum potency against cancerous cells.

This document provides information about a pilot study that aims to evaluate the feasibility and safety of using cytomegalovirus-specific, anti-HIV chimeric antigen receptor (CMV-HIV CAR) T cells as a potential immunotherapy for people living with HIV. The study focuses on the use of CAR T cells engineered to target HIV-infected cells, with the goal of eliminating these cells. The researchers propose using autologous CMV-specific T cells, which can be stimulated by endogenous CMV, to address the issue of low persistence of CAR T cells. The study is in its early stages and aims to assess the presence and effectiveness of CMV/HIV-CAR T cells in healthy individuals living with HIV. [Extracted from the article]

Researchers at the University of Twente in Enschede, Netherlands have developed a new method for capturing circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples. The method, called flow enrichment target capture Halbach-array (FETCH), reduces cell clumping and allows for the processing of larger fractions of DLA samples. The researchers found that using FETCH resulted in a significant increase in the number of CTCs detected compared to the current CellSearch method. This research has the potential to improve the clinical utility of CTCs in the diagnosis and treatment of cancer. [Extracted from the article]

A clinical trial, NCT06253520, is currently underway to test a cancer treatment that combines modified white blood cells with a targeted vaccine. The trial is open to adults with certain solid tumors that have spread after treatment. Participants will undergo leukapheresis to collect white blood cells, followed by a hospital stay and chemotherapy drugs. Modified white cells will then be infused, and a vaccine will be administered. Follow-up visits will occur, and participants will need to stay in touch with the gene therapy team for 15 years. The trial is not yet recruiting participants, and the estimated completion date is June 15, 2033. The study is open to all genders and is being conducted in the United States under the regulation of the U.S. FDA. Data from the study will be shared. The study is led by Dr. Steven A Rosenberg at the National Cancer Institute and covers various topics related to cancer, including antibodies, antigens, vaccines, chemotherapy, immunotherapy, and solid cancer. [Extracted from the article]

This document provides information about a clinical trial, NCT06240520, that aims to find a functional cure for HIV. The trial will investigate the effectiveness of different drug combinations in treating HIV-1 infection. The study will enroll 49 participants and is expected to be completed by October 2025. The eligibility criteria for participants are outlined, and the study is being conducted in the Netherlands and sponsored by the Erasmus Medical Center. [Extracted from the article]

A patent has been issued to Enlivex Therapeutics RDO Ltd. for therapeutic pooled blood apoptotic cell preparations. These preparations have the potential to treat immune disorders, autoimmune diseases, cytokine release syndrome, cytokine storms, cancer, and inflammatory diseases. The method involves administering a pharmaceutical composition containing irradiated mononuclear-enriched early apoptotic cells to prolong the survival of patients with these conditions. The invention aims to provide a safe, reliable, reproducible, and effective approach to prevent or ameliorate graft-versus-host disease (GVHD) in patients undergoing allogeneic blood or marrow transplantation. [Extracted from the article]

A patent application has been submitted for a blood processing and treatment system that includes a separator for separating blood into its components and a disposable fluid circuit. The system also includes a controller that can direct the collection and treatment of blood components, store information based on historical data and other input, and calculate recommended procedure settings. The system aims to optimize the collection and treatment of mononuclear cells (MNCs) and stem cells for therapeutic purposes. The patent application provides detailed descriptions of the system and methods for optimizing blood component collection and treatment procedures. [Extracted from the article]

This document provides information on a Phase I/II clinical study being conducted in China to evaluate the effectiveness and safety of a chimeric antigen receptor T-cell therapy called GC012F in patients with relapsed/refractory multiple myeloma. The study is open to both male and female participants aged 18-75 who have received at least three prior lines of therapy and meet specific laboratory and organ function requirements. Eligible subjects will receive a single dose of GC012F infusion after lymphodepletion. The study is currently recruiting and is expected to be completed by June 2026. [Extracted from the article]

A patent application titled "Methods Of Making Chimeric Antigen Receptor-Expressing Cells" has been published online. The application describes methods for producing immune effector cells, such as T cells, that can be engineered to express a chimeric antigen receptor (CAR). The methods involve using techniques like elutriation or density gradient centrifugation to purify the desired immune effector cells and remove impurities. These methods aim to simplify the manufacturing process, improve the quality of the final product, and enhance the effectiveness of CAR-expressing cell therapy products. The application suggests that this method could have potential applications in cancer treatment and gene therapy. [Extracted from the article]